UBS Group AG - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 51 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
UBS Group AG ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$2,434,457
-7.3%
81,858
-43.8%
0.00%0.0%
Q2 2023$2,625,387
+176.3%
145,693
+146.2%
0.00%
Q1 2023$950,238
-35.7%
59,168
-26.7%
0.00%
-100.0%
Q4 2022$1,476,700
+822.9%
80,694
+891.4%
0.00%
Q3 2022$160,000
-55.3%
8,139
-57.6%
0.00%
Q2 2022$358,000
-76.2%
19,180
-72.0%
0.00%
-100.0%
Q1 2022$1,504,000
+0.3%
68,493
+29.7%
0.00%
Q4 2021$1,500,000
+235.6%
52,820
+148.8%
0.00%
Q3 2021$447,000
+609.5%
21,227
+414.1%
0.00%
Q1 2021$63,000
+110.0%
4,129
+96.7%
0.00%
Q4 2020$30,000
-81.1%
2,099
-76.9%
0.00%
Q2 2020$159,000
+31.4%
9,093
+10.7%
0.00%
Q1 2020$121,000
-71.8%
8,216
-51.9%
0.00%
Q4 2019$429,000
+210.9%
17,087
+85.7%
0.00%
Q3 2019$138,000
+711.8%
9,199
+1242.9%
0.00%
Q2 2019$17,000
-98.3%
685
-98.4%
0.00%
Q1 2019$988,000
+5388.9%
43,416
+7196.8%
0.00%
Q4 2018$18,000
-61.7%
595
-63.7%
0.00%
Q3 2018$47,0001,6370.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q4 2018
NameSharesValueWeighting ↓
Versant Venture Management, LLC 2,030,616$31,028,0006.04%
5AM Venture Management, LLC 1,362,286$20,816,0003.75%
Burrage Capital Management LLC 272,393$4,162,0003.37%
Altium Capital Management LP 361,930$5,530,0001.54%
Vivo Capital, LLC 2,214,138$33,832,0001.19%
Bain Capital Life Sciences Investors, LLC 1,071,428$16,371,0000.93%
Perceptive Advisors 3,659,381$51,606,0000.65%
New Leaf Venture Partners, L.L.C. 141,000$2,154,0000.50%
DRIEHAUS CAPITAL MANAGEMENT LLC 2,003,688$30,616,0000.45%
Opaleye Management Inc. 188,000$2,873,0000.42%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders